RaQualia Pharma Inc.
4579.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | ¥8,311,846 | ¥14,865,092 | ¥25,834,271 | ¥24,598,845 |
| - Cash | ¥3,141,929 | ¥3,714,984 | ¥3,675,450 | ¥2,345,306 |
| + Debt | ¥3,452,334 | ¥367,718 | ¥222,338 | ¥39,067 |
| Enterprise Value | ¥8,622,251 | ¥11,517,826 | ¥22,381,159 | ¥22,292,606 |
| Revenue | ¥3,107,575 | ¥1,901,202 | ¥2,918,038 | ¥2,776,233 |
| % Growth | 63.5% | -34.8% | 5.1% | – |
| Gross Profit | ¥2,481,816 | ¥1,656,149 | ¥2,686,452 | ¥2,455,559 |
| % Margin | 79.9% | 87.1% | 92.1% | 88.4% |
| EBITDA | ¥188,271 | -¥111,801 | ¥1,004,736 | ¥1,023,587 |
| % Margin | 6.1% | -5.9% | 34.4% | 36.9% |
| Net Income | -¥495,031 | -¥323,662 | ¥723,390 | ¥755,788 |
| % Margin | -15.9% | -17% | 24.8% | 27.2% |
| EPS Diluted | -22.87 | -14.98 | 34.47 | 36.04 |
| % Growth | -52.7% | -143.5% | -4.4% | – |
| Operating Cash Flow | ¥180,945 | -¥718,596 | ¥1,480,084 | ¥366,027 |
| Capital Expenditures | -¥96,707 | -¥222,205 | -¥31,905 | -¥105,418 |
| Free Cash Flow | ¥84,238 | -¥940,801 | ¥1,448,179 | ¥260,609 |